A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder

PURPOSE: This phase 3 clinical trial evaluated the efficacy and safety of viloxazine extended-release capsules (VLX-ER) as a monotherapy for attention-deficit/hyperactivity disorder (ADHD) in adolescents (12–17 years). METHODS: Eligible subjects (n = 310) were randomized to receive once-daily 200 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Nasser, Azmi, Liranso, Tesfaye, Adewole, Toyin, Fry, Nicholas, Hull, Joseph T., Busse, Gregory D., Chowdhry, Fatima, Cutler, Andrew J., Jones, Nandita Joshi, Findling, Robert L., Schwabe, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Contributions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244935/
https://www.ncbi.nlm.nih.gov/pubmed/34181360
http://dx.doi.org/10.1097/JCP.0000000000001404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244935/
https://www.ncbi.nlm.nih.gov/pubmed/34181360
http://dx.doi.org/10.1097/JCP.0000000000001404

Ejemplares similares